UNSPSC 51282706: Oritavancin

A type of lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.

UNSPSC 51282706 Oritavancin is a Commodity code used by state and local health agencies to procure pharmaceutical products, though the recent opportunities tagged under this code show limited direct oritavancin activity. The code encompasses antibiotic and emergency-response pharmaceuticals supplied through state health departments, county health systems, and public health initiatives. State and local buyers use this code to source specialized drugs for public health stockpiles, community health programs, and emergency preparedness — typically leveraging piggyback contracts through established pharmaceutical consortiums or competitive bid processes to control costs and ensure supply chain continuity.

Activity under this code appears concentrated in health-focused state and local procurement offices rather than general municipal buying. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets under IFB 26482DPHPREPDB53392 (a completed award, not an open opportunity). Seminole County, Florida posted an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building. Recent activity clusters in Florida and Illinois; both procurements followed competitive invitation-for-bid processes with fixed pricing and multi-year terms including renewal options. No set-aside designations appear in the recent awards.